Novartis’ Pluvicto Receives Highest Clinical Benefit Score from ESMO for Advanced Prostate Cancer Novartis announced that its Pluvicto (lutetium (177Lu) vipivotide tetraxetan) has received the highest possible score of 5 …
Tag: